The best test for the world's most expensive disease.
NeuroScreen® testing service is a novel blood-based diagnostic tool for Alzheimer's disease that allows early detection - before patients become symptomatic - a key factor in treatment efficiency. Our algorithm examines leukocytes to predict the presence and quantity of amyloid plaques in the brain, the pathological manifestation of Alzheimer’s disease.
About
NeuroQuest's team is comprised of medical experts and business professionals from around the world with extensive experience in innovation, development, and clinical research.
Our mission is to provide patients and physicians with NeuroScreen® testing service, our accurate and affordable blood test for screening and monitoring asymptomatic Alzheimer’s disease.
NeuroScreen®
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by cognitive decline, functional impairment, and dementia. It is caused by the accumulation of amyloid plaque (Aβ42) in the brain, which can begin up to 20 years before the appearance of symptoms. While recent data indicate that treatments for AD are significantly more effective when given to asymptomatic individuals, there has been no effective way to identify these patients until now.
Research shows that as we age, our body goes through an array of changes. Our immune system weakens over time, making us more susceptible to new diseases. Experts hypothesized that this natural process makes it easier for Aβ42 to enter the brain, and harder for our body to clear it out. In other words, they believe that Alzheimer's disease might have an immune component to it. NeuroQuest has developed the NeuroScreen® testing service, a novel, blood-based diagnostic tool for preclinical AD. The service is based on our unique algorithm that uses immune blood-based biomarkers (leukocytes) to predict the presence and quantity of Aβ42 in the brain, allowing us to detect the disease before the appearance of symptoms.
Frequently Asked Questions (FAQ)
The problem that NeuroQuest is trying to solve is identifying asymptomatic Alzheimer's Disease (AD) individuals as early and accurately as possible. Experts agree that early detection of AD is an essential tool of intervention for asymptomatic patients as it can enhance the efficiency of recently approved FDA drugs for treating and preventing AD from progressing.
While others have attempted to measure p-tau and amyloid-beta plaque accumulation following the appearance of symptoms (e.g. cognitive decline, memory loss), NeuroQuest decided to utilize the immune system to predict such accumulation before symptoms appear.
NeuroQuest has developed NeuroScreen® testing service, a novel, blood-based diagnostic tool for Alzheimer's Disease (AD) based on the specific response of the immune system to the disease. The assay utilizes immune cells from peripheral blood as biomarkers to predict the presence and quantity of Aβ42 in the brain.
NeuroScreen® testing services provide the only blood-based assay that can track the accumulation and the quantity of Aβ42 in the brain even in asymptomatic individuals, making it an affordable and easy-to-administer diagnostic tool. It is the only blood-based assay that does not rely on some species of p-tau and provides significantly higher accuracy at lower cL levels.
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by cognitive decline, functional impairment, and dementia. An estimated 6.7 million Americans of all ages had Alzheimer’s disease in 2023 (Centers for Disease Control) and more than 55 million people are believed to be living with Alzheimer’s disease or other dementias worldwide (Alzheimer’s Disease International). The number of people with dementia is projected to double by 2040 and more than triple by 2060. The global economic burden of AD and related dementias is projected to reach $16.9 trillion by 2050.
The disease is caused by the accumulation of amyloid plaque (Aβ42) in the brain, which can begin up to 20 years before the appearance of symptoms. Recently approved FDA drugs for treating AD have demonstrated their ability to decrease the brain amyloid load. However, these treatments have shown limited efficacy, as research determined that once passed a certain threshold, the damage brought to the brain by Aβ42 is irreversible. Recent data indicate that treatments for AD are significantly more effective when given to asymptomatic individuals, but there has been no effective way to identify these patients until now.
NeuroScreen® testing service will change the world by detecting the disease in millions of asymptomatic individuals.
NeuroScreen® test service offers tremendous value to:
Patients and their families:
-
Enables access to new treatments
-
Reduces cost, time, and impact of tests and delayed diagnosis
-
Enables financial and care planning
-
Facilitates appropriate use and monitoring of medication
Healthcare providers & clinicians:
-
Helps improve patient care
-
Saves costs of repeated and/or multiple tests
-
Reduces cost and impact of inappropriate, ineffective drug use and/or screening tests
-
Reduces ongoing care costs with patients functioning longer
-
Provides easy to administer, accurate diagnostic tool
-
Strengthens diagnostic arsenal
Pharmaceutical companies:
-
Allows for easy and practical identification of asymptomatic individuals most likely to respond to newly developed disease-modifying treatments
-
Reduces drug development costs and time
-
Increased efficiency with earlier, better diagnosis
-
We're preparing to submit an FDA De Novo application for a breakthrough device designation. We are currently wrapping up our clinical research study which will conclude early 2025, a substantial milestone on our journey to secure FDA approval for NeuroScreen® test services. We plan to begin sales by early 2026 for clinical research purposes. Our vision is to gradually change the standard of care to a point where any person over the age of 55 can easily screen for Alzheimer's through their primary healthcare provider as a customer procedure.
“The scientific community and the FDA believe that it is critical to identify and study patients with very early Alzheimer's disease before there is too much irreversible injury to the brain. It is in this population that most researchers believe that new drugs have the best chance of providing meaningful benefit to patients.” - Russell Katz, MD, Director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research